Table 5. Selected trials of radiotherapy combined with tyrosine kinase inhibitors in oligopersistent oncogene-driven NSCLC.
| Author, ref. | No pts | Molecular status | Therapy | Median PFS (months) | Median OS (months) | Toxicity |
|---|---|---|---|---|---|---|
| Gomez et al., (87) | 49 |
EGFR+ 6 ALK+ 2 No aberration 41 |
Systemic therapy + local consolidative therapy | 14.2 | 41.2 | G3 in local consolidative therapy group: esophagitis 2 patients, anaemia 1 patient, pneumothorax 1 patient, abdominal pain 1 patient, No G4-5 toxicities |
| Elamin et al., (90) | 12 | EGFR+ | EGFR TKI + SBRT, HRT or surgery | 36 | NR | No G4 toxicities |
| Xu et al., (91) | 51 | EGFR+ | EGFR TKI + Arm A: SBRT to all residual metastatic sites | 20.6 | 40.9 | G≥3, esophagitis 16.9%, pneumonitis 7.7% |
| Arm B: SBRT to primary tumor and oligometastatic sites | 15.6 | 34.1 | ||||
| Arm C: no SBRT | 13.9 | 30.8 |
ref, reference; pt, patient; PFS, progression free survival; OS, overall survival; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; SBRT, stereotactic body radiotherapy; NR, not reached; HRT, hypofractionated radiotherapy.